Search Within

Sandra Endres

Formats
  1. Meeting Abstract (5)
  2. Journal Article (2)
Groups
  1. Center for Pancreatic Cancer Research (7)
  2. Department of Medicine (7)
  3. Gastrointestinal Oncology Service (7)
  4. Nursing (7)
  5. Solid Tumor Oncology Division (7)
  6. Biostatistics Service (2)

More Groups

People
  1. Gary Schwartz (7)
  2. David Kelsen (5)
  3. William Tong (5)
  4. Andreas Kaubisch (4)
  5. David Spriggs (4)
  6. Eileen O'Reilly (4)

More People

Years
  1. 2004 (1)
  2. 2002 (3)
  3. 2001 (2)
  4. 1999 (1)
Publications
  1. Clinical Cancer Research (2)
  2. Proceedings of the American Association for Cancer Research Annual Meeting (2)
  3. Anti-Cancer Drugs (1)
  4. European Journal of Cancer (1)
  5. Journal of Clinical Oncology (1)
Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (1)
  3. Elsevier Inc. (1)
  4. Lippincott Williams & Wilkins (1)

Results (7)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of sequential raltitrexed followed by bolus 5-fluorouracil in patients with advanced colorectal cancer
    Journal Article

    Schwartz, G. K.; Bertino, J.; Kemeny, N.; Saltz, L.; Kelsen, D.; Tong, W.; Welch, M.; Endres, S.; Dimery, I.
    Anti-Cancer Drugs (2004)

    Fulltext@MSK | Save
  • Response to the combination of bryostatin-1 and paclitaxel is dose-dependent
    Meeting Abstract

    Kortmansky, J.; Shah, M.; Ilson, D.; Kaubisch, A.; Endres, S.; Welch, M.; Gonen, M.; Kelsen, D. P.; Schwartz, G. K.
    Proceedings of the American Association for Cancer Research Annual Meeting (2002)

    Fulltext@MSK | Save
  • Phase I and pharmacokinetic study of LY293111, an orally available small molecule known to be an LTB4 receptor antagonist, 5-lipoxygenase inhibitor and peroxisome proliferator activated receptor-gamma agonist (PPAR gamma)
    Meeting Abstract

    Budman, D. R.; Schwartz, G. K.; Endres, S.; Welch, M.; O'reilly, E.; Barile-Thiem, B.; Brail, L. H.; De Alwis, D. P.; Cleverly, A.; Weitzman, A.
    European Journal of Cancer (2002)

    Fulltext@MSK | Save
  • Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors
    Journal Article

    Schwartz, G. K.; O'reilly, E.; Ilson, D.; Saltz, L.; Sharma, S.; Tong, W.; Maslak, P.; Stoltz, M.; Eden, L.; Perkins, P.; more...
    Journal of Clinical Oncology (2002)

    Fulltext@MSK | Save
  • A phase IB clinical trial of the sequence dependent combination of paclitaxel (P) and cisplatin (C) with the cyclin dependent kinase (CDK) inhibitor flavopiridol in patients with advanced solid tumors
    Meeting Abstract

    Shah, M. A.; Kaubisch, A.; O'reilly, E.; Sharma, S.; Endres, S.; Welch, M.; Tong, W.; Spriggs, D.; Schwartz, G. K.
    Proceedings of the American Association for Cancer Research Annual Meeting (2001)

    Fulltext@MSK | Save
  • A phase I/pharmacologic study of UCN-01 in combination with 5-fluorouracil in patients with advanced solid tumors
    Meeting Abstract

    Shah, M. A.; Kortmansky, J.; Kelsen, D. P.; Hseuh, C.; Kaubisch, A.; Spriggs, D.; Gonen, M.; Tong, W.; Endres, S.; Schwartz, G. K.
    Clinical Cancer Research (2001)

    Fulltext@MSK | Save
  • Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors
    Meeting Abstract

    Schwartz, G. K.; Kaubisch, A.; Saltz, L.; Ilson, D.; O'Reilly, E.; Barazzuol, J.; Endres, S.; Stoltz, M.; Tong, W.; Kelsen, D. P.; more...
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save